Lithuania has built a global reputation for excellence in biotechnology research and manufacturing.
Lithuanian researchers are constantly at the cutting edge – whether that’s the award-winning work of gene-editing pioneer Virginijus Šikšnys and his team at the Vilnius University Institute of Biotechnology, or the innovations coming out of Thermo Fisher Scientific’s global manufacturing and R&D centre in Vilnius. As an EU leader for investment in open R&D infrastructure, Lithuania’s contribution to biotech can only get bigger.
With major global players joining a host of local innovators, Life Sciences is Lithuania’s fastest-growing industry. Its value-added has more than quadrupled over the last seven years.
In total, 8% of Lithuania’s entire student body is enrolled in Life Sciences programmes. High-flyers include the Vilnius-Lithuania iGEM team, who won first place at the world’s largest and most prestigious Synthetic Biology competition, iGEM.
In 2018, a EUR 50 million investment fund focusing on biotechnology was established to drive funds for Lithuania-based biotech startups. You can find out more about the new fund here.
To discover more about investing in Life Sciences, come and talk to the team from Invest Lithuania at J.P. Morgan. We look forward to seeing you there!